Medical device and MedTech insights, news, tips and more

Aesculap Inc. Announces U.S. Launch of Hydrocephalus Valve

June 3, 2020


Aesculap Inc., in partnership with The Christoph Miethke GmbH & Co. KG (MIETHKE), is pleased to announce the launch of the valve, the latest generation of Hydrocephalus valve technology. Its unique gravitational technology is integrated with a fixed differential pressure unit in one valve, allowing for a simple, position-dependent solution.


The valve is the only adjustable gravitational valve in the market with an integrated fixed pressure differential valve. It provides customization of the opening pressure during the most active time of the day, i.e., the upright body position. The integration of the fixed pressure differential valve addresses the posture changes.

“We are very pleased to be able to continue to provide healthcare teams with new and innovative solutions,” said Chuck DiNardo, President of Aesculap Inc. “With our strong partnership with MIETHKE comes an impactful collaborative effort to bring better Hydrocephalus solutions to patients, such as the new valve.”

“The patient is our priority and we will continue to invest in research and development to create better solutions. Our focus on Hydrocephalus valves creates an expertise and openness to future developments that allows us to serve in a way that will improve the lives that we touch,” said Christoph Miethke, CEO and Founder of MIETHKE, the manufacturer of Hydrocephalus valves for Aesculap Inc. is located in Potsdam, Germany.

According to the Hydrocephalus Association, it is estimated that over 1,000,000 people in the United States currently live with Hydrocephalus.1 Shunt therapy is the most common way to treat Hydrocephalus, which is caused by excessive cerebrospinal fluid in the brain, causing build up and pressure that can lead to symptoms such as chronic headaches, vomiting, abnormal head enlargement and could lead to death. However, despite the shunts’ life-saving purpose, implantation has been riddled with high failure rates, causing multiple revisions and surgeries for an individual with the condition.2 Using gravitational systems have demonstrated good clinical outcomes in patients and reduced revisions compared to other valves.3,4,5,6

“This newest addition to the valve portfolio continues our tradition of offering uncompromised pressure adaptation through our gravitational systems,” said Odra Anderson, Product Manager for Aesculap, Inc. The valve is the smallest adjustable gravitational valve in the U.S. market. Its soft touch mechanism allows for comfortable adjustment. The design features an “active-lock mechanism” that protects from unintentional reprogramming7, not only after an MRI but also from everyday magnets such as smartphones8, toys9,10, tablets11, headphones12, nurse badges13 and hearing devices14,15. Its design is robust and durable, made with highly bio-compatible titanium,16,17 oxidized to display a shade of blue.

See Full Press Release: Aesculap Inc. Announces U.S. Launch of™ Hydrocephalus Valve | BioSpace

Written by: Aesculap, Inc

Legacy MedSearch has more than 30 years of combined experience recruiting in the medical device industry. We pride ourselves on our professionalism and ability to communicate quickly and honestly with all parties in the hiring process. Our clients include both blue-chip companies and innovative startups within the MedTech space. Over the past 10 years, we have built one of the strongest networks of device professionals ranging from sales, marketing, research & , quality & regulatory, project management, field service, and clinical affairs.

We offer a variety of different solutions for hiring managers depending on the scope and scale of each individual search. We craft a personalized solution for each client and position with a focus on attracting the best possible talent in the shortest possible time frame.

Are you hiring?

Contact us to discuss partnering with Legacy MedSearch on your position.

More insights

March 7, 2024
FDA Clears Dexcom’s First Over-the-Counter Continuous Glucose Monitor
Learn More
March 1, 2024
FDA greenlights Boston Scientific’s Novel Drug-Coated Balloon for Coronary In-Stent Restenosis
Learn More
February 21, 2024
Sparrow BioAcoustics Launches Software That Turns a Smartphone into a Stethoscope 
Learn More

Begin your legacy now. We are your medtech and medical device talent advisory firm.